The latest price target for KalVista Pharma (NASDAQ:KALV) was reported by Cantor Fitzgerald on September 9, 2024. The analyst firm set a price target for $0.00 expecting KALV to fall to within 12 months (a possible -100.00% downside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for KalVista Pharma (NASDAQ:KALV) was provided by Cantor Fitzgerald, and KalVista Pharma reiterated their overweight rating.

There is no last upgrade for KalVista Pharma

There is no last downgrade for KalVista Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KalVista Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KalVista Pharma was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.

While ratings are subjective and will change, the latest KalVista Pharma (KALV) rating was a reiterated with a price target of $0.00 to $0.00. The current price KalVista Pharma (KALV) is trading at is $9.60, which is out of the analyst’s predicted range.